Razones para desarrollar una pedagogía de la educación en valores

Based on the observation made in this study, the following recommendations are hereby suggested:

1. visual analogue scale (VAS) should always be used for SCD patients presenting with VOC;

2. routine blood film for malaria parasite should be made mandatory during VOC, and where this is not available, empirical anti-malarial therapy should be given in patients with associated fever, jaundice, and severe anaemia; and

3. A stratified blinded study should be carried out to compare efficacy of paludrine and daraprim as a form of prophylaxis in individuals with SCD.

Limitations:

1. Monitoring and recording of adherence to prophylaxis was difficult due to poor recall.

2. Automated High performance liquid chromatography would have been preferred for the determination of sickled cells in view of its high accuracy, but this was not available for this study.

REFERENCES

1. Serjeant GR, Serjeant BE. Sickle Cell Disease 3rd ed. Oxford University press 2001.

2. Guideline: Guidelines for the management of the acute painful crisis in sickle cell disease; British Journal of Haematology 2003; 120: 744-752.

3. Weatherall DJ. Genetic disorder of Haemoglobin In: Hoffbrand AV, Lewis S.M;

editors. Postgraduate Haematology 4^th ed. Heinemann London 1997: 91-119 4. Olujohungbe A., Yardumian A, Cinkotai KI. New treatment strategies for sickle

cell disease. Postgraduate Doctor (Africa); 1998; vol. 20 (3): 68 – 74

5. Serjeant GR, Serjeant BE. The Epidemiology of sickle cell disorder. A challenge for Africa. Archives of Ibadan medicine. 2001 (vol. 2): 46-52.

6. World Health Organization, Genera. New perspectives; Malaria Diagnosis;

Report of a Joint WHO/USAID informal consultation 25-27 Oct. 1999.

7. Gullet P. Insecticide- treated nets in Africa: where do we stand? Africa Health 2001;Vol. 23 (6): 20- 23.

8. Escoffery CT, Shirley SE. Autopsy findings and causes of death in sickle cell disease. Postgraduate Doctor (Africa).2000; Vol. 23 (3): 64-69.

9. Akinyanju O. Issues in the management and control of sickle cell disorder.

Archives of Ibadan medicine. 2000; vol. 2 (2): 39-41.

10. Serjeant GR. Historical review: The emerging understanding of sickle cell disease. British Journal of Haematology.2001,112:3-18.

11. Bunn FH. Pathogenesis and treatment of sickle cell disease. New England Journal of Medicine. 1997;vol. 337 (11) : 762- 769.

12. Serjeant GR. The geography of sickle cell disease: Opportunities for

13. Esan GJF. The Thalassaemia syndromes in Nigeria. British Journal of Haematology. 1970; 19: 47-56.

14. Baiyeroju AM. Ocular complications of sickle cell disorder. Archives of Ibadan Medicine. 2001; Vol. 2 (2): 57-59.

15. Gladwin MT, Schechter AN, Shelhemer JH et al. The acute chest syndrome in sickle cell disease: Possible role of Nitric oxide in its pathophysiology and treatment. America Journal of Respiratory and Critical care Medicine. 1999; Vol 159:1368-1376.

16. Fields EL. Phenotypic variation in sickle cell disease: An Analysis; In treatise submitted to Harvard University in partial fulfilment of the requirements of Biology 91R Oct 23, 1996 (revised Oct 27, 2000).

17. Steinberg MH, Hebbel RP. The clinical diversity of sickle cell anaemia: Genetic and cellular modulation of disease severity. Am. J. Haematology 1983;14:405-411.

18. Ibidapo MO, Akinyanju OO. Acute Sickle Cell Syndromes in Nigerian adults.

Clinical Lab. Haematology. 2000;22:151-155.

19. Edington GM, Laing WN. Relationship between Haemoglobin C and S and malaria in Ghana. British Medical Journal 1957; 144(July):143- 145.

20. Colbourne MJ, Edington GM. Sickling and Malaria in the Gold Coast. British Medical Journal 1956; 1:784-786.

21. Fleming AF, Storey J, Molineaux L, Iroko EA, Attai ED. Abnormal haemoglobins in the Sudan Savannah of Nigeria. I. Prevalence of haemoglobins and relationships between sickle cell trait, malaria and survival. Annals of

22. Nicholas JW. Malaria In: Gordon C, editor. Manson’s tropical diseases 20^th ed.

Saunders London 1998:1087-1164

23. Dormer P, Dierrich M, Kern P, Horstmatin RD. Ineffective erythropoiesis in acute human P. falciparum malaria. Blut. 1983;46:279-288.(med line)

24. Bryson ADM, Fleming AF, Edington GM. Splenomegaly in Northern Nigeria.

Acta Tropica. 1976;33:3-9.

25. Boudin C, Chumpitazi B, Dziegiel M et al. Possible role of Specific Immunoglobulin M antibodies to Plasmodium falciparum antigens in immuno protection of humans living in a hyperendemic area, Burkina Faso Journal of Clinical Microbiology 1993; March: 636-641.

26. W.H.O: Report of the Scientific working group meeting on malaria, Geneva, 24 -27 March, 2003.

27. Federal Ministry of health, National malaria and vector control division:

National antimalaria treatment Policy and Guidelines. ( Feb. 2005 )

28. David KP, Marbiah NT, Greenwood BM, Petersen E. Hyperpigmented dermal macules in children following the administration of maloprim for chemoprophylaxis. Transaction of the Royal Society of Trop. Med. And Hygiene. 1997;(91):204

29. Ali ME, Ahmed HA, Abdulaziz A. Salmonella as a causative organism of various infections in patient with sickle cell disease. Annals of Saudi Medicine 2003;

23(6): 358-362

30. Serjeant GR, Ceulaer CDE, Lethbridge R et al. The painful crisis of homozygous sickle cell disease: Clinical Features; British Journal of Haematology 1994;

87:586-591.

31. Odum CU, Anorlu RI, Dim SI, Oyekan TO. Pregnancy outcome in HbSS-sickle cell disease in Lagos, Nigeria. West African Journal of Medicine 2002; 21 (1):

19-23.

32. Diggs LW. Sickle Cell Crises. The American Journal of Clinical Pathology 1965 Vol 44, No1;1-18.

33. Akinola NO, Stevens SME, Franklin IM et al. Sub-clinical ischaemic episodes during the steady state of sickle cell anaemia. Journal of Clinical Pathology.

1992;45:902-906.

34. Fatusi OA, Durosinmi MA. Mental nerve palsy in a population of Nigerians with sickle cell disorder. Nigerian Clinical Review 2001; May/June: 32-35.

35. Schong JJ, Lard LR, Rojer RA et al. New Concept in assessing sickle cell disease severity. Am. J. Haematology 1998(May);58:61-66.

36. Platt OS, Brambilla JD, Rosse WF et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. New England Journal of Medicine.1994;23 (330):1639 – 1644.

37. Vichinsky EP, Styles LA, Colangelo EC et al. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood 1997;vol. 89(5):1787-1792.

38. Leikin SL, Gallagher D, Kinney TR. et al. Mortality in children and adolescents with sickle cell disease. Paediatrics 1989; 84: 500-508.

39. Thomas AN, Pattison C, Serjeant GR. Cause of death in sickle cell disease in Jamaica. British Medical Journal. 1982; 285:633-635.

40. Parfrey NA, Moore W, Hutchins GM. Is pain crisis a cause of death in sickle cell disease? American Journal of Clinical Pathology 1985; 84: 209-212.

41. Bailey K, Morriss JS, Thomas P, Serjeant, GR. Foetal haemoglobin and early manifestations of homozygous sickle cell disease. Arch Dis. Child 1992;67:517-522.

42. Ferster A, Vermylen C, Cornu G et al. Hydroxyurea for the treatment of severe sickle cell anaemia. A paediatric clinical trial. Blood 1996;(88)6:1960-1964.

43. Falusi AG, Esan GJF Foetal haemoglobin in sickle cell anaemias in Nigerians.

Afr. J. Med and Medical Sciences.1989;18:145-149.

44. Salawu L Study of relationship between HbF level, some haematological indices and persistent splenomegaly in Nigerians with sickle cell disorder. In Thesis submitted to the Postgraduate Medical College of Nigeria. 1998: 45pages.

45. Steinberg MH, Embury SH. Alpha-Thalassaemia in blacks- Genetic and clinical aspects and interaction with sickle haemoglobin gene. Blood; Vol 68(5): 985-990.

46. Graido-Gonzalez E, Doherty JC, Bergreen EW et al. Plasma Endothelin –1, cytokine and prostaglandin E2 levels in sickle cell disease and Acute vaso- occlusive crisis; Blood 1998; Vol 92 (7) (Oct 1): 2551-2555.

47. Osariogiagbon UR, Choong S, Belcher JD, Vercellotti GH, Paller MS, Hebbel RP. Reperfusion injury Pathophysiology in sickle transgenic mice. Blood 2000;96:314-320.

48. Osariogiagbon UR. Newer concepts of the pathogenesis of sickle cell disorder : The evidence for inflammation. Archives of Ibadan Medicine 2001.; Vol 2. (2) : 41-45.

49. Akinola NO, Stevens SME, Franklin M et al. Rheological changes in the prodromal and established phases of sickle cell vaso-occlusive crisis. British Journal of Haematology 1992;81:598-602.

50. Stuart J, Stone PCW, Akinola NO et al. Monitoring the acute phase response to vaso-occlusive crisis in sickle cell disease. J. Clin. Pathol. 1994;47:166-169.

51 Franco RS, Yasin Z, Lohmann JM. et al. The survival characteristics of dense cells. Blood 2000; 96(10):3610-3618.

52 Irene R. The role of hydroxyurea in sickle cell disease. British Journal of Haematology 2003;120: 177-186

53 Garnham PC. Malarial immunity in Africans: effects in infancy and early childhood. Annals of Tropical Medicine and Parasitology. 1949 vol.73(4):301-309.

54 Molineaux L, Fleming AF, Cornille-Brogger R, Kagan I, Storey J. Abnormal In the Sudan Savannah of Nigeria. Malaria immunoglobulins and anti malaria antibodies in sickle cell disease. Annals of Tropical Medicine and Parasitology 1979; vol 73(4): 301-309.

55 Abjah UMA, Aken’ova YA. Levels of malaria-specific immunoglobulin G in Nigerian sickle cell dsease patients with and without splenomegaly. Nigerian Journal of Medicine 2003: 12(1); 32-38.

56 Gavrilis P, Rothenberg S. P, Guy R. Correlation of low serum IgM levels with absence of splenic tissue in sickle cell disease syndrome. The American Journal of Medicine 1974 (57): 542-545.

57 Araoye MO. Research Methodology with statistics for health and social sciences. Nathadox Publishers. March 2004: 115-129.

58 Bain BJ, Bates I. Dacie and Lewis’ Practical Haematology, 9^th ed. Church hill Living stone. Edinburgh; 2001: 19-99.

59 Anthony M. Rapid diagnostic tests for malaria parasites. Clinical Microbiology

60 Cheesbrough M. Medical Laboratory Normal for Tropical countries (Vol. 1) 2^nd ed. English Language Book Society, 1998: 239-258.

61 Wong DL, Hocken B, Eaton M et al. “Modified” pain rating scale: In Wong’s Essentials of paediatric Nursing, 6th ed.,St Louis, 2001:1301

62 Jensen M, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods Pain 1986 ; 27 :117-26

63 McCaffery M, Pasero C. Pain rating scale: In Pain: Clinical Manual. Mosby Inc. 1999: 63

APPENDIX 1

ASSESSMENT OF PAINFUL CRISIS AT PRRESENTATION

Name:……… Age:……….

Sex:……….. Hb. Type: ………

Hosp. No:………..…… Date:………..

Time:………...…

SECTION A

1. Where is your pain? (Specify)

i. Limbs (indicate)……….

ii. Chest iii. Abdomen iv. Back /Spine

v. Others (Indicate) ……….

1b. Type of pain – dull …, sharp…., colicky…., burning (peppery)…, throbbing…, others(specify)………

2. Patient’s Assessment of pain intensity^61,62

0 – No pains 5 – Moderate pain 10- Worst pain possible

2a. Duration of Pain – 1-6hrs….…, 6-12hrs…….., 12-24hrs………,

0 5 10

2b. Medication taken for pains (tick) a. Paracetamol b. Pethidine c. DF 118 d. Morphine e. Co-proxamol

f. Others (specify):……….

3.Additional Medication taken before reporting in the day care/casualty ….Yes/No If Yes , Please mention them below:

i.

ii.

iii.

4. Did you take antimalaria medication? Yes/No

Which ones?--- 5. Did you take antibiotics? Yes/No

Which ones?:---

SECTION B

Physicians Assessment (tick one) 1. Pain Rating⁶³

[ ] No pains [ ] Mild pain [ ] Moderate pain [ ] Severe pain [ ] Very severe pain

2. Require hospital admission ……….…….. Yes/No

APPENDIX II